Asimov develops a platform that integrates synthetic biology, biophysical simulations, and machine learning to engineer mammalian cell lines for the production of biologics and gene therapies. This technology enables healthcare companies to optimize the design and manufacturing processes of genetic circuits, improving efficiency and scalability in therapeutic applications.
Funding
$204.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Engineering mammalian cell lines for biologics and gene therapies is a complex and time-consuming process, often requiring extensive trial-and-error to achieve optimal production yields and desired therapeutic properties. Traditional methods lack the precision and scalability needed to efficiently design and manufacture advanced therapies.
Solution
Asimov offers an integrated platform that combines synthetic biology, biophysical simulations, and machine learning to streamline the engineering of mammalian cell lines. The platform enables users to design, simulate, and optimize genetic systems for various cell types and applications. By providing engineered host cells, validated genetic parts, and cloud-based design software, Asimov facilitates the intelligent design of living systems for advanced therapeutic development. The platform supports the production of protein therapeutics, viral vectors for gene therapy, and programmable medicines with precise transgene expression control.
Target Audience
Asimov's platform is designed for biotech companies, pharmaceutical firms, and research institutions involved in the development and manufacturing of biologics, gene therapies, and other advanced therapeutics.
Features
- Engineered, GMP-grade host cell lines with supporting regulatory documentation
- Extensive library of experimentally validated genetic parts, including transposases, expression vectors, and inducible systems
- Cloud-based software for designing, simulating, and optimizing genetic systems
- AI-driven models for cell line and bioprocess design tailored to specific molecules
- CHO Edge system routinely achieves titers of 5-11 g/L across modalities
- AAV Edge suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
- LV Edge Packaging System to optimize lentivirus production